Skip to main content
SpringerLink
Log in

Hepatobiliary complications of oral contraceptives

  • Clinical Reviews
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Forrest JD, Fordyce RR. U.S. woman’s contraceptive attitudes and practice: how have they changed in the 1980’s? Fam Plann Perspect. 1988;20:112–8.

    Article  PubMed  CAS  Google Scholar 

  2. Vessey M, Lawless M, Yeates D. Efficacy of different contraceptive methods. Lancet. 1982;1:841–2.

    Article  PubMed  CAS  Google Scholar 

  3. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of 50- and 30-µg estrogen preparations. Br Med J. 1980;280:1157–61.

    PubMed  CAS  Google Scholar 

  4. Bottiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering estrogen content. Lancet. 1980;1:1097–101.

    Article  PubMed  CAS  Google Scholar 

  5. Porter JB, Jick H, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol. 1987;70:29–32.

    PubMed  CAS  Google Scholar 

  6. Meade TW. Oral contraceptives, clotting factors and thrombosis. Am J Obstet Gynecol. 1982;142:758–61.

    PubMed  CAS  Google Scholar 

  7. Zafrani ES, Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med. 1983;143:495–502.

    Article  PubMed  CAS  Google Scholar 

  8. Collaborative Group for the Study of Stroke in Young Women. Oral contraception and increased risk of cerebral ischemia or thrombosis. N Engl J Med. 1973;288:871–8.

    Article  Google Scholar 

  9. Connell EB. Oral contraceptives. The current risk-benefit ratio. J Reprod Med. 1984;29:513–23.

    PubMed  CAS  Google Scholar 

  10. Wynn V, Godsland I. Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med. 1986;31:898–905.

    Google Scholar 

  11. Wall DM, Roos MP. Update on combination oral contraceptives. Am Fam Pract. 1990;42:1037–48.

    CAS  Google Scholar 

  12. DeLia JE, Emery MG. Clinical pharmacology and common minor side effects of oral contraceptives. Clin Obstet Gynecol. 1981;24:879–92.

    PubMed  CAS  Google Scholar 

  13. Larsson-Cohn U. Oral contraceptives and liver function tests. Br Med J. 1965;1:1414–5.

    PubMed  CAS  Google Scholar 

  14. Stoll BA, Andrews JT, Motteran R. Liver damage from oral contraceptives. Br Med J. 1966;1:960–1.

    Google Scholar 

  15. Kreek MJ, Sleisenger MH, Jeffries GH. Recurrent cholestatic jaundice of pregnancy with demonstrated estrogen sensitivity. Am J Med. 1967;43:795–803.

    Article  PubMed  CAS  Google Scholar 

  16. Fast BB, Roulston TM. Idiopathic jaundice of pregnancy. Am J Obstet Gynecol. 1963;88:314–21.

    Google Scholar 

  17. Boake WC, Schade SG, Morrissey JF, Schaffner F. Intrahepatic cholestatic jaundice of pregnancy following Enovid-induced cholestatic jaundice. Ann Intern Med. 1965;63:302–8.

    PubMed  CAS  Google Scholar 

  18. Ylostola P. Liver function in cholestasis of pregnancy and preeclampsia — with special reference to bromsulphthalein tests. Acta Obstet Gynecol Scand. 1970;49(suppl 4):1–53.

    Article  Google Scholar 

  19. Kleiner GJ, Kresch L, Arias IM. Studies of hepatic excretory function: II. The effect of norethynodrel and mestranol on bromsulphthalein sodium metabolism in women of childbearing age. N Engl J Med. 1965;273:420–3.

    Article  PubMed  CAS  Google Scholar 

  20. Allen JS, Tyler ET. Biochemical findings in long-term oral contraceptive usage: I. Liver function studies. Fertil Steril. 1967;18:112–23.

    Google Scholar 

  21. Kreek MJ, Sleisenger MH. Estrogen-induced cholestasis due to endogenous and exogenous hormone. Scand J Gastroenterol. 1970;7(suppl):123–31.

    CAS  Google Scholar 

  22. Kreek MJ. Female sex steroids and cholestasis. Semin Liver Dis. 1978;7:8–23.

    Google Scholar 

  23. Dalen E, Westerholm B. Occurrence of hepatic impairment in women jaundiced by oral contraceptives in their mothers and sisters. Acta Med Scand. 1974;195:459–63.

    Article  PubMed  CAS  Google Scholar 

  24. Reyes H, Ribalta J, Gonzalez MC, et al. Sulfobromophthalein clearance tests before and after ethinyl estradiol administration in women and men with a familial history of intrahepatic cholestasis of pregnancy. Gastroenterology. 1981;81:226–31.

    PubMed  CAS  Google Scholar 

  25. Arfwedson H. General pruritus of pregnancy: symptoms of liver dysfunction. Obstet Gynecol. 1956;7:274–6.

    PubMed  CAS  Google Scholar 

  26. Holzbach RT, Sanders JH. Recurrent intrahepatic cholestasis of pregnancy. JAMA. 1965;193:204–206.

    Google Scholar 

  27. Sandovsky E, Eliakim M, Schenker JR. Pruritus gravidarum of hepatic origin. Israel J Med Sci. 1970;6:540–3.

    Google Scholar 

  28. Topp JR, Charles B. Pruritus of pregnancy: symptoms of hepatic dysfunction with report of two cases. Can Med Assoc J. 1961;85:724–6.

    PubMed  CAS  Google Scholar 

  29. Furhoff AK. Itching in pregnancy. Acta Med Scand. 1974;196:403–10.

    Article  PubMed  CAS  Google Scholar 

  30. Shaw D, Frohlick J, Wittman BA, Willms M. A prospective study of 18 patients with cholestasis of pregnancy. Am J Obstet Gynecol. 1982;142:621–5.

    PubMed  CAS  Google Scholar 

  31. Scharschmidt BF, Goldberg HI, Schmid R. Approach to the patient with cholestatic jaundice. N Engl J Med. 1983;308:1515–9.

    Article  PubMed  CAS  Google Scholar 

  32. Schenker S, Balint J, Schiff L. Differential diagnosis of jaundice: report of a prospective study of 61 proven cases. Am J Dig Dis. 1962;7:449–63.

    Article  Google Scholar 

  33. Wheeler PG, Theodossi A, Pickford R, et al. Non-invasive techniques in the diagnosis of jaundice — ultrasound and computerized tomography. Gut. 1979;20:196–9.

    PubMed  CAS  Google Scholar 

  34. O’Connor KW, Snodgrass PJ, Snowder JF, et al. A blinded prospective study comparing four current non-invasive approaches in the differential diagnosis of medical versus surgical jaundice. Gastroenterology. 1983;84:1498–504.

    PubMed  CAS  Google Scholar 

  35. Lance P, Bevan PG, Hoult JG, Paten A. Liver biopsy in “difficult” jaundice. Br Med J. 1977;2:236.

    PubMed  CAS  Google Scholar 

  36. Krook PM, Allen FG, Bush WH Jr, et al. Comparison of real-time cholecystsonography and/or cholecystography. Radiology. 1980;135:145–8.

    PubMed  CAS  Google Scholar 

  37. Baron RL, Stanley RJ, Lee JK, et al. A prospective comparison of the evaluation of biliary obstruction using computerized tomography and ultrasonography. Radiology. 1982;145:91–8.

    PubMed  CAS  Google Scholar 

  38. Gross BH, Harter LP, Gore RM, et al. Ultrasonic evaluation of common bile duct stone: prospective comparison with endoscopic retrograde cholangiopancreatography. Radiology. 1983;146:467–9.

    Google Scholar 

  39. Mueller PR, Harbin WP, Ferrucci JT Jr, et al. Fine needle transhepatic cholangiography: reflection after 450 cases. AJR. 1981;136:85–90.

    PubMed  CAS  Google Scholar 

  40. Mueller PR, van Sonnenberg E, Simeone JF. Fine needle transhepatic cholangiography: indications and usefulness. Ann Intern Med. 1982;97:567–72.

    PubMed  CAS  Google Scholar 

  41. Ellas E, Hamlyn AN, Jain S, et al. A randomized trial of percutaneous transhepatic cholangiography with CIBA needle versus endoscopic retrograde cholangiography for bile duct visualization in jaundice. Gastroenterology. 1976;71:439–43.

    Google Scholar 

  42. Matzen P, Hanbek A, Holst-Christensen J, et al. Accuracy of direct cholangiography by endoscopic or transhepatic route in jaundice—a prospective study. Gastroenterology. 1981;81:237–41.

    PubMed  CAS  Google Scholar 

  43. Cohen L, Lewis C, Arias IM. Pregnancy, oral contraceptives and family jaundice with predominantly conjugated hyperbilirubinemia (Dubin-Johnson syndrome). Gastroenterology. 1972;62:1182–90.

    PubMed  CAS  Google Scholar 

  44. Zimmerman HJ. Liver disease caused by medicinal agents. Med Clin North Am. 1975;59:897–909.

    PubMed  CAS  Google Scholar 

  45. Zimmerman HJ, Malddry WC. Toxic and drug induced hepatitis. In Schiff L, Schiff ER, eds. Disease of the liver. Philadelphia: J. B. Lippincott, 1987;591–668.

    Google Scholar 

  46. Plaa GL, Priestly BG. Intrahepatic cholestasis induced by drugs and chemicals. Pharmacol Rev. 1977;28:207–73.

    Google Scholar 

  47. Boston Collaborative Drug Surveillance Programme. Oral contraceptive and venous thromboembolic disease, surgically confirmed gall-bladder disease, and breast tumors. Lancet 1973;1:1399–404.

    Google Scholar 

  48. Bennion LJ, Ginsberg RL, Garnick MB, Bennett PH. Effects of oral contraceptives on the gallbladder of normal women. N Engl J Med. 1976;294:189–92.

    Article  PubMed  CAS  Google Scholar 

  49. Honore LH. Increased incidence of symptomatic cholesterol cholelithiasis in perimenopausal women receiving estrogen replacement therapy. J Reprod Med. 1980;25:187–90.

    PubMed  CAS  Google Scholar 

  50. Lynn J, Williams L, O’Brien J, et al. Effects of estrogen upon bile: implications with respect to gallstone formation. Ann Surg. 1973;178:514–24.

    Article  PubMed  CAS  Google Scholar 

  51. Davis RA, Kern F Jr. Effects of ethinyl estradiol and bile salt on cholesterol excretion: a possible mechanism for gallbladder disease. Clin Res. 1974;22:356A.

    Google Scholar 

  52. Nestle PJ, Hirsch EZ, Couzens EA. The effect of chloro-phenylisobutyric acid and ethinyl estradiol on cholesterol turnover. J Clin Invest. 1965;44:891–6.

    Google Scholar 

  53. Pellecchia D, McCallion M, Ryan JP. Influence of progesterone in vivo on antral and gallbladder motility in vitro. Fed Proc. 1981;40:577A.

    Google Scholar 

  54. Ryan JP, Bhojwani A, Wang MB. Effects of pregnancy on gastric motility in vivo and in vitro in the guinea pig. Gastroenterology. 1987;93:29–34.

    PubMed  CAS  Google Scholar 

  55. Everson GT, McKinley C, Lawson M, et al. Gallbladder function in the human female: effects of the ovulatory cycle, pregnancy and contraceptive steroids. Gastroenterology. 1982;82:711–9.

    PubMed  CAS  Google Scholar 

  56. Braverman DZ, Johnson ML, Kern F Jr. Effects of pregnancy and contraceptive steroids on gallbladder function. N Engl J Med. 1980;302:362–4.

    Article  PubMed  CAS  Google Scholar 

  57. Rodberg G, Asztely M, Cantor P, et al. Gastric and gallbladder emptying in relation to the secretion of cholecystokinin after a meal in late pregnancy. Digestion. 1989;42:174–80.

    Google Scholar 

  58. Rodberg G, Friman S, Svanvik J. The influence of pregnancy and contraceptive steroids on the biliary tract and its reference to cholesterol gallstone formation. Scand J Gastroenterol. 1989;25:97–102.

    Google Scholar 

  59. Rodberg G, Svanvik J. Influence of pregnancy, oophorectomy and contraceptive steroids on gallbladder concentrating function and hepatic bile flow in the cat. Gut. 1986;27:10–4.

    Google Scholar 

  60. Kern F, Everson GT, DeMark B, et al. Biliary lipids, bile acids, and gallbladder function in the human female: effects of contraceptive steroids. J Lab Clin Med. 1982;99:798–805.

    PubMed  CAS  Google Scholar 

  61. Layde PM, Vessay MP, Yeates D. Risk factors for gallbladder disease: a cohort study of young women attending family planning clinics. J Epidemol Community Health. 1982;36:274–8.

    CAS  Google Scholar 

  62. Ramcharan S, Pellegrin FA, Ray R, Hsu JP. The Walnut Creek Contraceptive Drug Study, Vol. III. Washington, DC: United States Government Printing Office, 1981. NIH Publication No. 81-564.

    Google Scholar 

  63. Royal College of General Practitioners’ Oral Contraceptive Study. Oral contraceptives and gallbladder disease. Lancet. 1982;36:274–8.

    Google Scholar 

  64. Strom BL, Tamragouri RN, Morse ML, et al. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther. 1986;39:335–41.

    Article  PubMed  CAS  Google Scholar 

  65. Turrill FL, McCarron N, Mikkelsen WP. Gallstones and diabetes: an ominous association. Am J Surg. 1961;102:184–90.

    Article  PubMed  CAS  Google Scholar 

  66. Tucker LE, Tansedahl TN, Newmark SR. Prevalence of gallstones is obese Caucasian American women. Int J Obes. 1982;6:247–51.

    PubMed  CAS  Google Scholar 

  67. Coyle JJ, Hoyt DB, Sedeghat A. Relationship of intestinal bypass operations and cholelithiasis. Surg Forum. 1980;31:139–41.

    Google Scholar 

  68. Jordan RA. Cholelithiasis in sickle-cell disease. Gastroenterology. 1957;33:952–8.

    PubMed  CAS  Google Scholar 

  69. Phillips JC, Gerald PE. The incidence of cholelithiasis in sickle-cell disease. Am J Roentgenol. 1971;113:27–8.

    CAS  Google Scholar 

  70. Bates GA, Brown CH. Incidence of gallbladder disease in chronic hemolytic anemia (spherocytosis). Gastroenterology. 1952;21:104–9.

    PubMed  CAS  Google Scholar 

  71. Ihasz M, Griffith CA. Gallstones after vagotomy. Am J Surg. 1981;141:48–50.

    Article  PubMed  CAS  Google Scholar 

  72. Ahlberg J, Angelin B, Einarsson K, et al. Biliary lipid composition in normo- and hyperlipoproteinemia. Gastroenterology. 1980;79:90–4.

    PubMed  CAS  Google Scholar 

  73. Roy CC, Weber AM, Morin CL, et al. Abnormal biliary lipid composition in cystic fibrosis: effect of pancreatic enzymes. N Engl J Med. 1977;297:1301–5.

    Article  PubMed  CAS  Google Scholar 

  74. Baum JK, Bookstein JJ, Holtz F, et al. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973;2:926–9.

    Article  PubMed  CAS  Google Scholar 

  75. Amerikas JA, Thompson NW, Frey CF, et al. Hepatic cell adenoma, spontaneous liver rupture and oral contraceptives. Arch Surg. 1975;110:548–57.

    Google Scholar 

  76. Edmondson HA, Henderson B, Benson B. Liver cell adenoma associated with the use of oral contraceptives. N Engl J Med. 1976;294:470–2.

    Article  PubMed  CAS  Google Scholar 

  77. Stauffer JQ, Hill RB. Systemic contraceptives and liver tumors. Ann Intern Med. 1976;85:122–3.

    PubMed  CAS  Google Scholar 

  78. Nissen ED, Kent DR, Nissen SE. Role of oral contraceptives in the pathogenesis of liver tumors. J Toxicol Environ Health. 1979;5:231–54.

    Article  PubMed  CAS  Google Scholar 

  79. Greer T. Hepatic adenoma and oral contraceptive use. J Fam Pract. 1989;28:322–6.

    PubMed  CAS  Google Scholar 

  80. Scott LD, Katz AR, Duke JH, et al. Oral contraceptives, pregnancy, and focal nodular hyperplasia of the liver. JAMA. 1984;251:1461–3.

    Article  PubMed  CAS  Google Scholar 

  81. Fitz JG. Oral contraceptives and benign tumors of the liver. West J Med. 1984;140:260–7.

    PubMed  CAS  Google Scholar 

  82. Prentice RL, Thomas DB. Epidemiology of oral contraceptives and disease. Adv Cancer Res. 1987;49:285–402.

    Article  PubMed  CAS  Google Scholar 

  83. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979;242:644–8.

    Article  PubMed  CAS  Google Scholar 

  84. Wavri WN. Primary neoplasm of the liver. Arch Pathol. 1944;37:367–76.

    Google Scholar 

  85. Adams YG, Huros AG, Fortner JG. Giant hemangiomas of the liver. Ann Surg. 1970;172:239–45.

    Article  Google Scholar 

  86. Huggins GR, Zucker PK. Oral contraceptives and neoplasia: 1987 update. Fertil Steril. 1987;47:733–61.

    PubMed  CAS  Google Scholar 

  87. Jick H, Herman R. Oral contraceptive induced benign liver tumors—the magnitude of the problem. JAMA. 1978;240:828–9.

    Article  PubMed  CAS  Google Scholar 

  88. Klatsin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology. 1977;73:386–94.

    Google Scholar 

  89. Sorensen TI, Baden H. Benign hepatocellular tumors. Scand J Gastroenterol. 1975;10:113–9.

    PubMed  CAS  Google Scholar 

  90. Salvo AF, Schiller A, Athanasoulis C, et al. Hepatoadenoma and focal nodular hyperplasia: pitfalls in radiocolloid imaging. Radiology. 1977;125:451–5.

    PubMed  CAS  Google Scholar 

  91. Kerlin D, Davis GL, McGill DB, et al. Hepatic adenoma and focal nodular hyperplasia. Clinical pathology and radiologic features. Gastroenterology. 1983;84:994–1002.

    PubMed  CAS  Google Scholar 

  92. Knowles DM, Casarella WJ, Johnson PM, et al. The clinical, radiologic, and pathologic characterizations of benign hepatic neoplasms. Medicine. 1978;57:223–37.

    Article  PubMed  Google Scholar 

  93. Welch TJ, Sheedy PT, II, Johnson CM, et al. Focal nodular hyperplasia and hepatic adenoma: comparison of angiography, CT, US, and scintigraphy. Radiology. 1985;156:543–57.

    Google Scholar 

  94. Mathieu D, Bruneton JN, Drouillard J, et al. Hepatic adenomas and focal nodular hyperplasia: dynamic CT study. Radiology. 1986;160:53–8.

    PubMed  CAS  Google Scholar 

  95. Consensus Conference. Magnetic resonance imaging. JAMA. 1988;259:2132–8.

    Article  Google Scholar 

  96. Stark DD, Felder RC, Wittenberg J. Magnetic resonance imaging of cavernous hemangiomas of the liver: tissue specific characterizations. Am J Radiol. 1986;145:213–22.

    Google Scholar 

  97. Ishak KG, Rabin L. Benign tumors of the liver. Med Clin North Am. 1975;59:995–1013.

    PubMed  CAS  Google Scholar 

  98. Tesluk H, Lawrie J. Hepatocellular adenoma: its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med. 1981;105:296–9.

    PubMed  CAS  Google Scholar 

  99. Gordon SE, Reddy KR, Livingstone AS, et al. Resolution of a contraceptive—steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med. 1986;105:547–9.

    PubMed  CAS  Google Scholar 

  100. Davis M, Postmann B, Searle M, et al. Histologic evidence of carcinoma in a hepatic tumor associated with oral contraceptives. Br Med J. 1975;180:14–9.

    Google Scholar 

  101. Neuberger J, Nunnerly HB, David M, et al. Oral contraceptive associated liver tumors: occurrence of malignancy and difficulties in diagnosis. Lancet. 1980;1:273–6.

    Article  PubMed  CAS  Google Scholar 

  102. Edmondson HA, Reynolds TB, Henderson B, et al. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med. 1977;86:180–2.

    PubMed  CAS  Google Scholar 

  103. Sherlock S. Progress report: hepatic reactions to drugs. Gut. 1979;20:634–48.

    PubMed  CAS  Google Scholar 

  104. Mariani A, Livingstone AS, Pereiras RV, et al. Progressive enlargement of an hepatic cell adenoma. Gastroenterology. 1979;77:1319–25.

    PubMed  CAS  Google Scholar 

  105. Marks WH, Thompson N, Applemann H. Failure of hepatic adenomas (HCA) to regress after discontinuance of oral contraceptives. An association with focal nodular hyperplasia (FNH) and uterine leiomyoma. Ann Surg. 1988;208:190–5.

    Article  PubMed  CAS  Google Scholar 

  106. Buhler H, Pirovino M, Akovbiantz A. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology. 1982;82:775–82.

    PubMed  CAS  Google Scholar 

  107. Weinmann MD, Chopra S. Tumors of the liver other than primary hepatocellular carcinoma. Gastroenterol Clin North Am. 1987;16:627–50.

    Google Scholar 

  108. David M, Portmann B, Searle M, et al. Histologic evidence of carcinoma in a hepatic tumor associated with oral contraceptives. Br Med J. 1975;4:496–8.

    Google Scholar 

  109. Glassberg AB, Rosenbaum EG. Oral contraceptives and malignant hepatoma. Lancet. 1976;1:479.

    Article  PubMed  CAS  Google Scholar 

  110. Pryor AC, Cohen RJ, Goldman RL. Hepatocellular carcinoma in a woman on long-term oral contraceptives. Cancer. 1977;40:884–8.

    Article  PubMed  CAS  Google Scholar 

  111. Ham JM, Stevenson D, Liddlelow AG. Hepatocellular carcinoma possibly induced by oral contraceptives. Am J Dig Dis. 1978;23:38s-40s.

    Article  Google Scholar 

  112. Vana J, Murphy GP. Primary malignant liver tumors: association with oral contraceptives. NY State J Med. 1979;79:321–5.

    CAS  Google Scholar 

  113. Shar SR, Kew MC. Oral contraceptives and hepatocellular carcinoma. Cancer. 1982;49:407–10.

    Article  PubMed  CAS  Google Scholar 

  114. Cote RJ, Urmacher C. Rhabdomyosarcoma of the liver associated with long-term oral contraceptive use. Am J Surg Pathol. 1990;14:784–90.

    Article  PubMed  CAS  Google Scholar 

  115. Silverberg E, Buring CC, Squires TS. Cancer statistics, 1990. Cancer. 1990;40:9–26.

    CAS  Google Scholar 

  116. Henderson BE, Preston-Martin S, Edmondson HA, et al. Hepatocellular carcinoma and oral contraceptives. Br J Cancer. 1983;48:437–40.

    PubMed  CAS  Google Scholar 

  117. Forman D, Vincent TJ, Doll R. Cancer of the liver and use of oral contraceptives. Br Med J. 1986;292:1357–61.

    CAS  Google Scholar 

  118. Neuberger J, Forman D, Doll R, et al. Oral contraceptives and hepatocellular carcinoma. Br Med J. 1986;292:1355–7.

    CAS  Google Scholar 

  119. Palmer JR, Rosenberg L, Kaufman DW, et al. Oral contraceptive use and liver cancer. Am J Epidemiol. 1989;130:878–82.

    PubMed  CAS  Google Scholar 

  120. Forma D, Doll R, Peto R. Trends in mortality from carcinoma of the liver and the use of oral contraceptives. Br J Cancer. 1983;48:349–54.

    Google Scholar 

  121. Goodman ZD, Ishak KG. Hepatocellular carcinoma in women: probable lack of etiologic association with oral contraceptive steroids. Hepatology. 1982;2:440–4.

    Article  PubMed  CAS  Google Scholar 

  122. Porter LE, Elm MS, Dugas MC. Characterization and quantitiation of human hepatic estrogen receptor. Gastroenterology. 1983;81:704–12.

    Google Scholar 

  123. Porter LE, Elm MS, Van Thiel DH, et al. Hepatic estrogen receptor in human liver disease. Gastroenterology. 1987;92:735–45.

    PubMed  CAS  Google Scholar 

  124. Gyorffy EJ, Bredfeldt JE, Black WC. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med. 1989;110:489–90.

    PubMed  CAS  Google Scholar 

  125. Meade TW, Chakarabarti R, Haines AP, et al. Haemostatis, lipid and blood-pressure profiles of women on oral contraceptives containing 50µg or 30µg estrogen. Lancet. 1977;2:948–51.

    Article  PubMed  CAS  Google Scholar 

  126. Kelly TM. Systemic effects of oral contraceptives. West J Med. 1989;141:113–6.

    Google Scholar 

  127. Carvalho ACA, Vaillancourt RA, Cabral RB, et al. Coagulation abnormalities in women taking oral contraceptives. JAMA. 1977;237:875–8.

    Article  PubMed  CAS  Google Scholar 

  128. Ecker JA, Mekittrick JE, Failing RM. Thrombosis of the hepatic veins: the “Budd-Chiari syndrome” — a possible link between oral contraceptives and thrombosis formation. Am J Gastroenterol. 1966;45:429–43.

    PubMed  CAS  Google Scholar 

  129. Langer B, Stone RM, Colapinto RF, et al. Clinical spectrum of the Budd-Chiari syndrome and its surgical management. Am J Surg. 1975;129:137–45.

    Article  PubMed  CAS  Google Scholar 

  130. Wu SM, Sprung OM, Klotz AP. Budd-Chiari syndrome after taking oral contraceptives. Am J Dig Dis. 1977;22:623–8.

    Article  PubMed  CAS  Google Scholar 

  131. Tavill AS, Wood EJ, Kreel, et al. The Budd-Chiari syndrome: correlation between hepatic scintigraphy and the clinical, radiological and pathological findings in nineteen cases. Gastroenterology. 1975;68:509–18.

    PubMed  CAS  Google Scholar 

  132. Powell-Jackson PR, Melin W, Canalese J, et al. Budd-Chiari syndrome: clinical patterns and therapy. Q J Med. 1982;51:79–88.

    PubMed  CAS  Google Scholar 

  133. Baert AL, Fevery J, Marchal G, et al. Early diagnosis of Budd-Chiari syndrome by computed tomography and ultrasonography: report of five cases. Gastroenterology. 1983;84:587–95.

    PubMed  CAS  Google Scholar 

  134. Alpert LI. Veno-occlusive disease of the liver. Case report and review of the literature. Hum Pathol. 1976;7:709–18.

    Article  PubMed  CAS  Google Scholar 

  135. Orloff MJ, Johansen KH. Treatment of Budd-Chiari syndrome by side-to-side portacaval shunt: experimental and clinical results. Ann Surg. 1978;188:494–512.

    Article  PubMed  CAS  Google Scholar 

  136. Mitchell MC, Boitnott JK, Kaufman S, et al. Budd-Chiari syndrome. Etiology, diagnosis and management. Medicine. 1982;61:199–218.

    Article  PubMed  CAS  Google Scholar 

  137. Malt RA, Dalton JC, Johnson RE, Gurewich V. Side-to-side portacaval shunt versus nonsurgical treatment of Budd-Chiari syndrome. Am J Surg. 1978;136:387–9.

    Article  PubMed  CAS  Google Scholar 

  138. Lewis JH, Tice HL, Zimmerman HJ. Budd-Chiari syndrome associated with oral contraceptive steroids: review of treatment of 47 cases. Dig Dis Sci. 1983;28:673–83.

    Article  PubMed  CAS  Google Scholar 

  139. Knapp WA, Ruebner BH. Hepatomas and oral contraceptives. Lancet. 1974;1:270–1.

    Article  PubMed  CAS  Google Scholar 

  140. Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis. 1981;1:116–28.

    PubMed  CAS  Google Scholar 

  141. van Erpecum KJ, Kreuning J, Ruiter DJ, et al. Generalized peliosis hepatis and cirrhosis after long-term use of oral contraceptives. Am J Gastroenterol. 1988;83:572–5.

    PubMed  Google Scholar 

  142. Nadell J, Kosek J. Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch Pathol Lab Med. 1977;101:405–10.

    PubMed  CAS  Google Scholar 

  143. Winkler K, Poulson H. Liver disease with periportal sinusoidal dilatation. A possible complication to contraceptive steroids. Scand J Gastroenterol. 1975;10:699–704.

    PubMed  CAS  Google Scholar 

  144. Camilleri M, Schafler K, Chadwick VA, et al. Periportal sinusoidal dilatation, inflammatory bowel disease, and the contraceptive pill. Gastroenterology. 1981;80:810–5.

    PubMed  CAS  Google Scholar 

  145. Zafrani ES, Pinaudeau Y, LeCudonnee B, et al. Focal hemorrhagic necrosis of the liver: a clinicopathological entity possibly related to oral contraceptives. Gastroenterology. 1980;79:1295–9.

    PubMed  CAS  Google Scholar 

  146. Jacobs MB. Hepatic infarction related to oral contraceptive use. Arch Intern Med. 1984;144:642–3.

    Article  PubMed  CAS  Google Scholar 

  147. Decherney AH. The use of birth control pills in women with medical disorders. Clin Obstet Gynecol. 1981;24:965–75.

    PubMed  CAS  Google Scholar 

  148. Berk PD, Wolkoff AW, Berlin NI. Inborn errors of biliary metabolism. Med Clin North Am. 1975;59:803–16.

    PubMed  CAS  Google Scholar 

  149. Minuk GY, Shaffer EA. Benign recurrent intrahepatic cholestasis. Evidence for an intrinsic abnormality in hepatocyte secretion. Gastroenterology. 1987;93:1187–93.

    PubMed  CAS  Google Scholar 

  150. Putterman C, Keidar S, Brook JG. Benign recurrent cholestasis — intrahepatic cholestasis — 25 years of follow-up. Postgrad Med J. 1987;63:295–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Alabama School of Medicine—Tuscaloosa Program, Box 870378, 35487-0378, Tuscaloosa, AL

    Michael C. Lindberg MD

Authors
  1. Michael C. Lindberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Received from the Department of Internal Medicine, University of Alabama School of Medicine—Tuscaloosa Program, Tuscaloosa, Alabama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindberg, M.C. Hepatobiliary complications of oral contraceptives. J Gen Intern Med 7, 199–209 (1992). https://doi.org/10.1007/BF02598014

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02598014

Keywords

Search

Navigation